— Know what they know.
Not Investment Advice
Also trades as: 0IJO.L (LSE) · $vol 0M · EX9.DE (XETRA) · $vol 0M

EXEL NASDAQ

Exelixis, Inc.
1W: +3.9% 1M: +11.9% 3M: +15.2% YTD: +49.4% 1Y: +71.1% 3Y: +212.6% 5Y: +205.5%
$65.35
+0.24 (+0.37%)
After Hours: $65.72 (+0.37, +0.56%)
Weekly Expected Move ±2.7%
$61 $63 $65 $66 $68
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Buy · Power 70 · $16.4B mcap · 214M float · 1.16% daily turnover · Short 56% of daily vol
Credit Risk of going bust: lower than 92% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.9%), Exelixis, Inc. would be worth roughly what it owes.
Total debt $165.9M against a stock market value of $16.37B.
Distance to default 15.69 (Merton model): prices to 2026-10-26, balance sheet 2026-07-03, debt counted $83.0M (short-term plus half of long-term), stock volatility 33.8%; Altman Z'' 7.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

No Supply Chain Data

No business relationships found for EXEL in SEC 8-K filings.

This may mean the company hasn't filed material agreements or acquisitions in the covered period (2021–2026), or the company may not have a CIK-to-ticker mapping.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms